DE69029398D1 - Hemmung von padgem-vermittelter zellbindung - Google Patents

Hemmung von padgem-vermittelter zellbindung

Info

Publication number
DE69029398D1
DE69029398D1 DE69029398T DE69029398T DE69029398D1 DE 69029398 D1 DE69029398 D1 DE 69029398D1 DE 69029398 T DE69029398 T DE 69029398T DE 69029398 T DE69029398 T DE 69029398T DE 69029398 D1 DE69029398 D1 DE 69029398D1
Authority
DE
Germany
Prior art keywords
padgem
inhibition
cell binding
mediated cell
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69029398T
Other languages
English (en)
Other versions
DE69029398T2 (de
Inventor
Bruce Furie
Eric Larsen
Alessandro Celi
Gary Gilbert
Barbara Furie
John Erban
Roberta Bonfanti
Denisa Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New England Medical Center Hospitals Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Application granted granted Critical
Publication of DE69029398D1 publication Critical patent/DE69029398D1/de
Publication of DE69029398T2 publication Critical patent/DE69029398T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Networks Using Active Elements (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69029398T 1989-10-20 1990-10-22 Hemmung von padgem-vermittelter zellbindung Expired - Lifetime DE69029398T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42488689A 1989-10-20 1989-10-20
PCT/US1990/006101 WO1991006632A1 (en) 1989-10-20 1990-10-22 Inhibition of padgem-mediated cell binding

Publications (2)

Publication Number Publication Date
DE69029398D1 true DE69029398D1 (de) 1997-01-23
DE69029398T2 DE69029398T2 (de) 1997-04-10

Family

ID=23684279

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69029398T Expired - Lifetime DE69029398T2 (de) 1989-10-20 1990-10-22 Hemmung von padgem-vermittelter zellbindung

Country Status (9)

Country Link
EP (1) EP0496832B1 (de)
JP (1) JPH05504470A (de)
AT (1) ATE146218T1 (de)
CA (1) CA2067250C (de)
DE (1) DE69029398T2 (de)
DK (1) DK0496832T3 (de)
ES (1) ES2097765T3 (de)
GR (1) GR3022011T3 (de)
WO (1) WO1991006632A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021956A1 (en) * 1992-05-05 1993-11-11 Cytel Corporation Antibodies to p-selectin and their uses
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
ATE224911T1 (de) * 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
CA2105997A1 (en) * 1991-03-11 1992-09-12 Bruce Furie Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component
CA2110495A1 (en) * 1991-06-10 1992-12-23 Robert M. Ippolito Immunosuppressive and tolerogenic oligosaccharide derivatives
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
JPH07507040A (ja) * 1991-09-10 1995-08-03 セントコー，インコーポレイテッド セレクチンによって介在される炎症のペプチド阻害剤
CA2120240A1 (en) * 1991-09-30 1993-03-31 Theresa M. Palabrica Inhibition of vascular narrowing using anti-padgen antibodies
JPH07501828A (ja) * 1991-12-18 1995-02-23 セントコー，インコーポレイテッド セレクチン類で仲介される炎症のペプチド阻害剤
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
EP0731709B1 (de) * 1992-05-11 2001-10-24 Corvas International, Inc. Neutrophilen inhibitoren aus nematoden
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
ATE256182T1 (de) * 1992-10-23 2003-12-15 Inst Genetics Llc Neuartiges p- selectin ligandenprotein
WO1994011498A1 (en) * 1992-11-16 1994-05-26 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
EP0804235A4 (de) * 1993-05-04 2001-09-19 Aeres Biomedical Ltd Antikörper gegen p-selectin und ihre verwendungen
AU2361395A (en) * 1994-04-28 1995-11-29 Genetics Institute Inc. Novel P-selectin ligand protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88308A0 (en) * 1987-11-17 1989-06-30 Scripps Clinic Res Peptides that block the binding of von willebrand factor
ATE224911T1 (de) * 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand

Also Published As

Publication number Publication date
CA2067250A1 (en) 1991-04-21
ATE146218T1 (de) 1996-12-15
EP0496832A4 (en) 1993-02-17
EP0496832A1 (de) 1992-08-05
GR3022011T3 (en) 1997-03-31
DE69029398T2 (de) 1997-04-10
EP0496832B1 (de) 1996-12-11
CA2067250C (en) 2008-06-17
WO1991006632A1 (en) 1991-05-16
ES2097765T3 (es) 1997-04-16
DK0496832T3 (da) 1996-12-30
JPH05504470A (ja) 1993-07-15

Similar Documents

Publication Publication Date Title
DE69029398T2 (de) Hemmung von padgem-vermittelter zellbindung
DE3783042T2 (de) System zur automatisierung von testen.
DE68901632D1 (de) Reaktionsgefaess zur durchfuehrung von aufeinanderfolgenden analytischen testen.
IT8019675A0 (it) Procedimento per rivelare ligandi in campioni di prova e relativo reagente analitico.
DE3671105D1 (de) Automatischer analysator mit freiem zugang zur probe.
DE3689856T2 (de) Analyseverfahren und vorrichtung für biologische specimen.
ATE76508T1 (de) Vorrichtung zur feststellung von okkultem blut.
DE68923389D1 (de) Detektorzelle für Flüssigkeitschromatographie.
ES511797A0 (es) "metodo para ensayar reacciones antigeno-anticuerpo".
DE3582758D1 (de) Verfahren und anordnung zur entdeckung von schmuggelsubstanz.
DE59109048D1 (de) Inhibitoren zur antikoagulierenden Vorbehandung von Blutproben
NO890867L (no) Fluidum-proevetaker, saerlig for benyttelse i en oljebroenn.
NO864113D0 (no) Fremgangsmaate for immonoassay, samt analysesett for dens utfoerelse.
DE68915767D1 (de) Selbsttätige, chemishe mehrfachproben-mehrfachreagens-analysierungsanordnung.
DE68914617D1 (de) Nachweisvorrichtung für Kathodenlumineszenzanalyse.
ES509142A0 (es) Procedimiento para determinar la presencia de una analito en una muestra sospechosa de contenerlo.
NO910202L (no) Fremgangsmaate for aa identifisere hydrokarbonfoerende lag iundergrunnsformasjoner.
DE3750084T2 (de) Anordnung für Einführung von Vorrissen in Keramikproben.
DE3853560D1 (de) Analytisches Element zur Vollblutuntersuchung.
DE69023426D1 (de) Behälter für Flüssigkeitsproben.
DE69021912D1 (de) Probeneinspritzzelle.
PT77153B (de) Drehzapfenlager fuer tueren insbesondere fuer pendeltueren
DE68908979T2 (de) Proben-Einspritzvorrichtung.
DE3778471D1 (de) Testreagens zur bestimmung von amylase.
ES2166996T3 (es) Metodo y reactivo para controlar los niveles en sangre de compuestos antiplaquetarios.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC., BOSTON

8364 No opposition during term of opposition